ArticleCureus2025
From Purines to Plaques: Serum Uric Acid as a Cardiometabolic Marker and Its Correlation With Dyslipidemia in Essential Hypertension.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Metabolic disturbances, particularly lipid abnormalities and increased uric acid levels, are commonly observed in essential hypertension and may play a role in endothelial injury and heightened cardiovascular risk. Assessing the relationship between serum uric acid and lipid abnormalities may enhance risk profiling in hypertensive patients. Methodology A hospital-based, cross-sectional study was conducted in the Department of General Medicine, Sree Balaji Medical College and Hospital, Chennai, from August 2023 to February 2025. In total, 60 adults aged 35-65 years with essential hypertension (blood pressure >140/90 mmHg) were included. Patients with diabetes, obesity, gout, systemic illnesses, alcohol or tobacco use, or prior lipid-lowering therapy were excluded. After obtaining informed consent, clinical details and anthropometric measures were collected. Fasting samples were analyzed for serum uric acid and lipid profile parameters. Associations between uric acid and lipid fractions were assessed. Results Of the 60 hypertensive individuals, 68.3% had hyperuricemia (≥7.0 mg/dL). This group exhibited significantly higher mean triglycerides (195.8 vs. 180.3 mg/dL), low-density lipoprotein (144.4 vs. 132.9 mg/dL), and very-low-density lipoprotein (40.9 vs. 37.1 mg/dL), along with lower high-density lipoprotein (45.2 vs. 47.3 mg/dL) compared to those with lower uric acid levels. Dyslipidemia was more prevalent among hyperuricemic patients (92.6% vs. 78.9%). Serum uric acid also showed a positive correlation with systolic blood pressure and body mass index. Conclusions Elevated serum uric acid is significantly associated with adverse lipid profiles in essential hypertension. Hyperuricemia may act as a metabolic marker, underscoring the importance of early detection and combined management of uric acid and lipid abnormalities to reduce cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.